American Academy of Allergy, Asthma, and Immunology Virtual Annual Meeting (AAAAI 2021)

Virtual 26 February 2021 - 01 March 2021

Tezepelumab triumphs in severe, uncontrolled asthma

12 Apr 2021 by

Treatment with the human monoclonal antibody tezepelumab reduced exacerbations and improved asthma control, lung function, and quality of life in adults and adolescents with severe, uncontrolled asthma, according to the phase III NAVIGATOR study presented as a poster at AAAAI 2021.

Tezepelumab triumphs in severe, uncontrolled asthma

12 Apr 2021

Face mask use does not impact oxygen saturation in asthma patients

26 Mar 2021 by

The use of face masks to reduce transmission of COVID-19 does not appear to affect oxygen saturation levels in individuals with asthma, according to a study presented at AAAAI 2021.

Face mask use does not impact oxygen saturation in asthma patients

26 Mar 2021

Novel jakinib stops the itch in teen AD

24 Mar 2021 by

The oral Janus kinase (JAK) inhibitor abrocitinib, otherwise called jakinib, does well in patients 12–17 years of age with atopic dermatitis (AD) in the phase III JADE TEEN study, providing instant itch relief.

Novel jakinib stops the itch in teen AD

24 Mar 2021

Omalizumab improves sleep outcomes in patients with CRSwNP

23 Mar 2021 by

Treatment with omalizumab improves sleep outcomes in patients with chronic rhinosinusitis with nasal polyps (CRSwNP), according to the POLYP 1 and 2* open-label extension (OLE) studies presented at AAAAI 2021.

Omalizumab improves sleep outcomes in patients with CRSwNP

23 Mar 2021

Dupilumab cuts exacerbations in difficult-to-treat type 2 asthma

19 Mar 2021 by

Dupilumab effectively prevents severe asthma exacerbations and improves lung function in patients with difficult-to-treat type 2 asthma, according to a post hoc analysis of the LIBERTY ASTHMA QUEST study presented at AAAAI 2021.

Dupilumab cuts exacerbations in difficult-to-treat type 2 asthma

19 Mar 2021

Benralizumab may help reduce OCS reliance in asthma

18 Mar 2021 by

Patients with asthma reliant on oral corticosteroids (OCS) may be able to gradually cease or reduce their OCS dose after initiating treatment with benralizumab, according to results of the phase IIIb PONENTE* trial.

Benralizumab may help reduce OCS reliance in asthma

18 Mar 2021

Budesonide reduces rhinitis symptoms in adults exposed to airborne pollution

17 Mar 2021 by

Treatment with an intranasal budesonide aqueous spray led to significantly reduced nasal symptoms in adults with rhinitis exposed to high levels of airborne pollution, according to a study presented at AAAAI 2021.

Budesonide reduces rhinitis symptoms in adults exposed to airborne pollution

17 Mar 2021

Mepolizumab benefits patients with severe asthma across the board

14 Mar 2021 by

The interleukin-5 (IL-5) inhibitor mepolizumab reduces asthma exacerbations in patients with severe asthma across a broad range of baseline clinical characteristics and regardless of comorbidities, according to studies presented at the 2021 AAAAI Meeting.

Mepolizumab benefits patients with severe asthma across the board

14 Mar 2021

Penicillin skin testing – how safe in pregnant women?

12 Mar 2021 by

Penicillin skin testing in pregnant women is safe both for the mum and the baby, experts assure at AAAAI 2021.

Penicillin skin testing – how safe in pregnant women?

12 Mar 2021

Berotralstat reduces HAE attacks regardless of baseline attack rates, prior treatment

09 Mar 2021 by

Subgroup analyses of the phase III APeX-2 trial presented at AAAAI 2021 showed that use of the oral plasma kallikrein inhibitor berotralstat led to consistent reductions in attack frequency in patients with hereditary angioedema (HAE), irrespective of baseline attack rates and prior prophylaxis.

Berotralstat reduces HAE attacks regardless of baseline attack rates, prior treatment

09 Mar 2021